Across four AACR posters, Ascentage reported preclinical synergy signals spanning hematologic and solid tumors: olverembatinib enhanced chemotherapy activity in endometrial carcinoma and combined with acalabrutinib in mantle cell lymphoma to deepen apoptosis and induce G0/G1 arrest; APG-2449 amplified the effect of dabrafenib plus trametinib in BRAF V600E models by suppressing compensatory signaling; and the EED inhibitor APG-5918 potentiated topoisomerase I agents in small-cell lung cancer with in vivo tumor growth inhibition and no significant body-weight loss in xenografts, alongside pharmacodynamic evidence of H3K27me3 reduction and SLFN11 upregulation.

The core development is a coordinated preclinical push into resistance-informed combinations using three assets at different stages of Ascentage’s portfolio. While olverembatinib is already marketed in China for CML and is under global registrational study, the company is signaling intent to expand the molecule’s reach into endometrial carcinoma and mantle cell lymphoma based on pathway biology and PRISM screening across 883 cell lines that flagged endometrial carcinoma sensitivity. In parallel, APG-2449’s FAK activity is being positioned to blunt adaptive reactivation under MAPK blockade in BRAF V600E melanoma and colorectal cancer, and APG-5918 is shown to epigenetically prime SCLC for DNA-damaging therapy by reversing PRC2-mediated silencing of SLFN11. The result is a preclinical dataset that ties each candidate to a defined resistance circuit and points toward rational, partnerable regimens.

Strategically, this is an expansion play that hedges against a concentrated hematology revenue base and a crowded late-stage BTK/BCL2 landscape. By anchoring on resistance biology and combination logic, Ascentage is aligning with regulatory and payer expectations for mechanistic justification in add-on regimens. The tension is familiar: synergy in controlled models often carries a toxicity tax in clinic, especially when multi-kinase agents are layered on chemotherapy or triplet targeted backbones. Olverembatinib’s broader kinase profile, which is an asset for pathway coverage, may heighten off-tumor effects in solid tumors; similarly, adding FAK inhibition to dabrafenib/trametinib or pairing an EED inhibitor with topoisomerase I agents increases the risk of overlapping myelosuppression and GI toxicity that can cap dose intensity.

For clinical operations, the near-term impact will be demand for early-phase, combination-heavy protocols spanning multiple indications, with biopsy-intensive pharmacodynamic readouts. Sites should anticipate serial tissue or liquid biopsies for markers such as H3K27me3, SLFN11, and pathway phospho-proteins, plus dense PK/PD sampling to navigate drug–drug interactions with acalabrutinib, cytotoxics, and BRAF/MEK inhibitors. CROs and labs with capability for on-treatment biomarker analytics and rapid safety adjudication will be central, as will supply-chain coordination for multi-sponsor drug sourcing. Regulators typically endorse these combinations when the preclinical rationale is strong, but early go/no-go decisions will hinge on tolerability at clinically relevant exposures and clear PD modulation in first-in-human combination cohorts.

Next, watch for IND-enabling packages to convert into Phase 1b dose-escalation and expansion studies, ideally through master protocols that can basket BRAF V600E tumors or segment endometrial carcinoma by FGFR2 or PI3K pathway status. Key risks include managing additive toxicities in triplets, demonstrating translational PD effects that correlate with early efficacy, and prioritizing among multiple combination paths to conserve cash and focus operations. Competitive dynamics also matter: FAK combinations have active programs elsewhere, non-covalent BTK combinations are reshaping MCL, and EED inhibitors are an emerging class with parallel entrants. The signal to track is whether Ascentage can show clean, biomarker-driven tolerability and early response rates that justify randomized combination studies—and whether it secures the cross-company collaboration needed to scale these regimens globally.

Source link: https://www.globenewswire.com/news-release/2026/04/20/3276678/0/en/Ascentage-Pharma-to-Present-Four-Promising-Preclinical-Studies-Demonstrating-the-Potential-of-Combination-Therapies-at-American-Association-for-Cancer-Research-AACR-2026-Annual-Mee.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.